Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- J&J Files Nipocalimab for Generalized Myasthenia Gravis in Japan
January 31, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
- Chugai, SoftBank in AI Deal to Speed Up Drug Development
January 31, 2025
- Chugai, GSK Join Hands in Anti-Dengue Antibody Development
January 31, 2025
- Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
- Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
- Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025
- Quviviq Off to Good Start in GP Promotion in December: Intage
January 31, 2025
- Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
- Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President
January 30, 2025
- Jazz Obtains Pharmaceutical Marketing License in Japan
January 30, 2025
- Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President
January 29, 2025
- ASKA, Susmed Initiate Clinical Study of PMS Therapeutic App
January 29, 2025
- PeptiDream/RayzeBio’s Peptide-Radionuclide Theranostic Enter Clinic
January 29, 2025
- GSK Files Depemokimab for Asthma and CRSwNP in Japan
January 29, 2025
- KalVista Files HAE Drug Sebetralstat in Japan
January 29, 2025
- Enhertu Approved for HER2-Low/Ultralow Breast Cancer
January 29, 2025
- Marubeni Invests in Healthcare Product Distributor in Africa
January 29, 2025
- Despite Spike in Flu Cases, Vaccine Shipments Down in FY2024: Wholesalers
January 28, 2025
- Nippon Shinyaku Bags US License Option for AB2 Bio’s Tadekinig Alfa
January 28, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…